

Norma Maugeri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9063028/publications.pdf>

Version: 2024-02-01

60
papers

3,233
citations

159585

30
h-index

155660

55
g-index

62
all docs

62
docs citations

62
times ranked

6924
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2074-2088.	3.8	426
2	To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps. <i>Cell Death and Differentiation</i> , 2019, 26, 395-408.	11.2	295
3	Patients with COVID-19: in the dark-NETs of neutrophils. <i>Cell Death and Differentiation</i> , 2021, 28, 3125-3139.	11.2	189
4	Reduction of Circulating Neutrophils Precedes and Accompanies Type 1 Diabetes. <i>Diabetes</i> , 2013, 62, 2072-2077.	0.6	177
5	The Neutrophil's Choice: Phagocytose vs Make Neutrophil Extracellular Traps. <i>Frontiers in Immunology</i> , 2018, 9, 288.	4.8	177
6	Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1323-1330.	3.8	169
7	Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and β_2 integrin-dependent cell clearance program. <i>Blood</i> , 2009, 113, 5254-5265.	1.4	129
8	Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	118
9	Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. <i>Autoimmunity</i> , 2012, 45, 584-587.	2.6	94
10	Selective up-regulation of the soluble pattern recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. <i>Arthritis and Rheumatism</i> , 2012, 64, 854-865.	6.7	89
11	Early and Transient Release of Leukocyte Pentraxin 3 during Acute Myocardial Infarction. <i>Journal of Immunology</i> , 2011, 187, 970-979.	0.8	82
12	Oxidative Stress Elicits Platelet/Leukocyte Inflammatory Interactions via HMGB1: A Candidate for Microvessel Injury in Systemic Sclerosis. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1060-1074.	5.4	81
13	Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. <i>Current Opinion in Hematology</i> , 2010, 17, 3-8.	2.5	78
14	Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. <i>Pharmacological Research</i> , 2017, 123, 146-156.	7.1	77
15	Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2593-2598.	3.8	75
16	Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-. <i>International Journal of Cardiology</i> , 2021, 324, 261-266.	1.7	65
17	Anti-TNF α agents curb platelet activation in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1511-1520.	0.9	57
18	An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. <i>PLoS ONE</i> , 2012, 7, e39484.	2.5	52

#	ARTICLE	IF	CITATIONS
19	Unconventional CD147â€dependent platelet activation elicited by SARSâ€CoVâ€2 in COVIDâ€19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 434-448.	3.8	50
20	Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2011, 118, 3359-3366.	1.4	49
21	Translational Mini-Review Series on Immunology of Vascular Disease: Mechanisms of vascular inflammation and remodelling in systemic vasculitis. <i>Clinical and Experimental Immunology</i> , 2009, 156, 395-404.	2.6	48
22	Application of 2-dimensional difference gel electrophoresis (2D-DIGE) to the study of thrombin-activated human platelet secretome. <i>Platelets</i> , 2008, 19, 43-50.	2.3	46
23	Leukocyte HMGB1 Is Required for Vessel Remodeling in Regenerating Muscles. <i>Journal of Immunology</i> , 2014, 192, 5257-5264.	0.8	39
24	Increased plasmatic NETs by-products in patients in severe obesity. <i>Scientific Reports</i> , 2019, 9, 14678.	3.3	38
25	The role of platelets in the pathogenesis of systemic sclerosis. <i>Frontiers in Immunology</i> , 2012, 3, 160.	4.8	35
26	Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. <i>European Journal of Pharmacology</i> , 1992, 216, 401-405.	3.5	33
27	Instructive influences of phagocytic clearance of dying cells on neutrophil extracellular trap generation. <i>Clinical and Experimental Immunology</i> , 2014, 179, 24-29.	2.6	33
28	Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis. <i>Stem Cells International</i> , 2016, 2016, 1-12.	2.5	33
29	Parnaparin, a low-molecular-weight heparin, prevents P-selectindependent formation of platelet-leukocyte aggregates in human whole blood. <i>Thrombosis and Haemostasis</i> , 2007, 97, 965-973.	3.4	32
30	Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. <i>Thrombosis Research</i> , 2012, 129, 267-273.	1.7	31
31	Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum. <i>Clinical and Experimental Immunology</i> , 2014, 175, 150-166.	2.6	29
32	Tissue Factor Expressed by Neutrophils: Another Piece in the Vascular Inflammation Puzzle. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 728-736.	2.7	29
33	Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: A clue to thromboembolic risks?. <i>Autoimmunity</i> , 2009, 42, 386-388.	2.6	28
34	Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2016, 7, 182.	4.8	27
35	Misunderstandings Between Platelets and Neutrophils Build in Chronic Inflammation. <i>Frontiers in Immunology</i> , 2019, 10, 2491.	4.8	24
36	Macrophages Guard Endothelial Lineage by Hindering Endothelial-to-Mesenchymal Transition: Implications for the Pathogenesis of Systemic Sclerosis. <i>Journal of Immunology</i> , 2019, 203, 247-258.	0.8	23

#	ARTICLE	IF	CITATIONS
37	Bet on NETs! Or on How to Translate Basic Science into Clinical Practice. <i>Frontiers in Immunology</i> , 2016, 7, 417.	4.8	22
38	Intraplatelet levels of VWF: AG and fibrinogen in myeloproliferative disorders. <i>Thrombosis Research</i> , 1987, 48, 311-319.	1.7	15
39	Effect of nitric oxide on megakaryocyte growth induced by thrombopoietin. <i>Translational Research</i> , 2001, 137, 261-269.	2.3	13
40	Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis. <i>Current Pharmaceutical Design</i> , 2014, 20, 567-574.	1.9	13
41	Anti-inflammatory action of apoptotic cells in patients with acute coronary syndromes. <i>Atherosclerosis</i> , 2009, 205, 391-395.	0.8	12
42	Evaluation of platelet function in essential thrombocythemia under different analytical conditions. <i>Platelets</i> , 2020, 31, 179-186.	2.3	12
43	Platelet Phagocytosis via P-selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 318-328.	5.6	12
44	Platelet function and intraplatelet von willebrand factor antigen and fibrinogen in myelodysplastic syndromes. <i>Thrombosis Research</i> , 1987, 46, 601-606.	1.7	10
45	Standardization in flow cytometry: correct sample handling as a priority. <i>Nature Reviews Immunology</i> , 2012, 12, 864-864.	22.7	10
46	Platelet clearance by circulating leukocytes: A rare event or a determinant of the immune continuum. <i>Platelets</i> , 2014, 25, 224-225.	2.3	8
47	Formation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) device. <i>Thrombosis and Haemostasis</i> , 2007, 97, 156-157.	3.4	8
48	Clinical and experimental evidences on the prothrombotic properties of neutrophils. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2010, 138, 50-52.	0.2	7
49	The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4982.	4.1	5
50	Purification and partial characterization of a bioactive substance from rat's vessel wall independent of prostacyclin production. <i>Thrombosis Research</i> , 1988, 52, 127-135.	1.7	4
51	The influence of sex and different segments of thoracic aorta on bioactive aortic substance (BAS) and prostacyclin (PGI ₂) synthesis. <i>Thrombosis Research</i> , 1989, 56, 19-27.	1.7	3
52	Adenosine triphosphate released from human mononuclear cells. <i>Thrombosis Research</i> , 1990, 59, 887-890.	1.7	3
53	Neutrophils and sepsis. <i>Lancet, The</i> , 2006, 368, 1153.	13.7	3
54	Biomarkers of vascular inflammation. Cell stress offers new clues. <i>International Journal of Cardiology</i> , 2017, 246, 18-19.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 680-713.	2.3	3
56	More on: tissue factor in neutrophils. Journal of Thrombosis and Haemostasis, 2005, 3, 1114-1114.	3.8	2
57	Partial purification of a bioactive substance(s) from human veins independent of prostacyclin production. Thrombosis Research, 1989, 55, 385-388.	1.7	1
58	Effect of histamine on human lymphocyte aggregation. Thrombosis Research, 1991, 61, 149-154.	1.7	1
59	Correction: Early and Transient Release of Leukocyte Pentraxin 3 during Acute Myocardial Infarction. Journal of Immunology, 2011, 187, 6582-6582.	0.8	1
60	Hormonal regulation on Bioactive Aortic Substance (BAS) production. Thrombosis Research, 1989, 56, 13-18.	1.7	0